I'm specialised in multi-jurisdictional contentious patent matters, with a particular focus in life sciences & healthcare and the tech & comms sector.
When I joined Bird & Bird in 2005, I was involved in a broad range of intellectual property tasks, including patents, trademarks, designs, domain names and unfair competition, both in contentious and non-contentious matters, for clients active in different sectors (life sciences, chemicals, telecommunications, fashion and luxury).
I then specialised in patent litigation in the pharmaceutical and biotechnological sectors.
On a daily basis I advise on issues relating to validity and infringement of patents and supplementary protection certificates, as well as on related regulatory issues concerning the reimbursement of generic medicinal products. In the last few years, I have been involved in a number of pan-European litigation in the field of pharmaceutical and biotechnological patents and supplementary protection certificates (including the patents related to pemetrexed, fulvestrant, tadalafil, rivastigmine patch, esomeprazole, rosuvastatin, quietiapine extended release, paracetamol and tramadol, second medical use of botulinum toxin, bimatoprost, fluvastatin, nebivolol, olanzapine, rituximab and the SPCs on telmisartan and hydrochlorothiazide, valsartan and hydrochlorothiazide, ezetimibe and simvastatin).
I am also experienced in patent litigation in the telecommunications sector . In particular, I have been involved in various litigation concerning standard essential patents (in particolar related to GSM, 3G, LTE, Wi-Fi, DVB-T2, ATSS and WSS technology), but also in defining the strategy of protection and enforcement of these patents and in managing the related competition issues.
I have contributed to various legal publications and articles on intellectual property law (including Managing Intellectual Property Magazine, The Life Sciences Law Review, Life Sciences Legal Practice Guide, Studi in memoria di Paola A .E. Frassi, Kluwer Trademark Litigation Smart Charts), and I'm member of the Editorial Board of EPLAW Patent Blog and of the European Copyright and Design Reports (Sweet & Maxwell).